Magnifygen is a Delaware Corporation headquartered in Rockville, Maryland. The mission of the company is to develop antibody-based drugs for treatment of cancer. The company was initially funded by SPEED Biosystems LLC and foreign angel investors.


Dazhi Lai

Dazhi (Alex) Lai, Ph.D.

Founder and CEO

Dr. Lai is an experienced immunologist trained at Yale and the NIH. He has over 10 years of experience in recombinant drug development. He was involved in the development of several approved drugs including recombinant human interferon-ω and recombinant anthrax vaccine. Dr. Lai is also the founder of SPEED Biosystems.
Todd Chappell

Todd Chappell, M.B.A

Chief Operating Officer

Mr. Chappell has over 10 years of experience in management of drug development operations. He was former VP of Operations at Shape Pharmaceuticals and Director of New Products at CombinatoRx Inc. He directly oversaw the advancement of three programs from assay stage into phase II human clinical studies, and was co-inventor on 10 product patents. Todd holds a B.S. from UCLA and a M.B.A. from Boston University.
Weizhou Zhang

Weizhou Zhang, Ph.D.

Research Collaborator

Dr. Zhang is an Assistant Professor of Pathology at the University of Iowa. He is an expert in breast cancer research and a collaborator with us on a pending NIH STTR grant. Dr. Zhang received his Ph.D. from Mount Sinai School of Medicine.